While toxicity and immunogenicity profiles of fluorescein conjugates may differ, it is reasonable to expect that the potential risk for the development of neutralizing antibodies within the given time window of days to few weeks for combined AML and HSPC targeting will be low [60], an assumption that will need future testing for each specific format. This evidence concerns the gene PSMA7 and acute myeloid leukemia.